Brenus Pharma funding news – Lyon-based Brenus Pharma Secures €22.2 Million in Series A Round Funding

Together, they join longtime investors Stéphane Legastellois (33 CALIFORNIE) and co-founder and main investor Jacques Gardette (BIOJAG). Furthermore, Brenus Pharma has benefited from non-dilutive funding from Bpifrance and the French government as a result of the France 2030 call for proposals.

The first-in-human proof-of-concept trial for the STC-1010 cancer vaccine in first-line settings for patients with metastatic colorectal cancer will be funded entirely by the revenues. Based on Brenus Pharma's "Stimulated-Tumor-(ghost)-Cells" technological platform, STC-1010 is the first potential vaccine.

Read also - Battolyser Systems funding news – Dutch-based Battolyser Systems Secures €30Million in Series A Round Funding

Adaptive and creative, this platform leverages a comprehensive understanding of the complexities of cancer to provide a novel kind of precision medicine, allowing Brenus Pharma to boost patients' immune systems by predicting the course of their illness.

The Chairman of Bio Jag, Jacques Gardette, stated: "Brenus Pharma has made significant progress. The fact that financial professionals have arrived at our fledgling business is evidence of the interest we are sparking. With the formation of Brenus Pharma and its subsequent sale to Novo Nordisk in 2023, we are fully committed to assisting the firm in realizing its aspirational objectives. I firmly believe that the Brenus team's unwavering dedication and inventiveness have established a strong basis for addressing one of the most intricate therapeutic problems in the world. Throughout its quick development, Brenus has proven to be a bold, successful, and resilient biotech company.

Marie Chambodut, Partner, and Investment Director at Angelor, added: “We are proud to lead this strategic transaction for Brenus Pharma to support the clinical development of their cancer vaccines, including STC-1010, the first and most advanced program to emerge from the platform. We look forward to joining Paul and his exceptional team in transforming Brenus into a global player in precision immuno-oncology, bringing solutions to millions of patients experiencing treatment failure, and contributing to the development of the French biotherapeutics industry.”

With the help of the money raised, the STC platform will be made available to humans by the end of the year. STC-1010, for example, will be used as a first-line treatment for patients with immunotherapies (pMMR/MSS and dMMR/MSI-H)-resistant metastatic colorectal cancer (mCRC) that is incurable. STC-1010 will also be expanded to treat other kinds of stomach tumors, like those of the liver and pancreas, concurrently. Brenus Pharma aims to expedite the advancement of its portfolio in additional solid tumor indications, particularly with STC-1020, our ongoing second candidate.

Hélène Sabatel, Investment Manager at Noshaq, said: “Together with our colleagues at InvestSud, we are delighted to support the Brenus Pharma team in the development of this cutting-edge technological platform, as we are convinced of its future impact for patients currently without concrete therapeutic solutions. We are also enthusiastic about the prospect of welcoming a Brenus R&D branch to the Liège region soon, and we hope that this new Franco-Belgian collaboration between two biotech ecosystems will provide the company with optimal support for its development.”

Paul Bravetti, Chief Executive Officer of Brenus Pharma, added: “We are delighted to welcome top-tier investors who have been part of recent French success stories (Mablink, Amolyt Pharma). This is an important milestone for Brenus Pharma, confirming the potential of the STC platform, and of STC-1010, which has already demonstrated solid proof of efficacy in various preclinical models. I would like to thank all our team for their motivation and their passionate work to rapidly bring a new therapeutic solution to patients. Our shared ambition is to position our platform at the forefront of the national and international scene, and to become a leader in next-generation cancer immunotherapies.”

About Brenus Pharma

Founded in Lyon, France, Brenus Pharma is a private biotechnology start-up that creates a platform technology to provide the best tumor-antigen-focused immunotherapy available.